Insulin Marketing Pharma Companies Regulation 
World of DTC Marketing
DECEMBER 14, 2021
WHAT’S HAPPENING: In the Build Back Better bill , Democrats are actually proposing limiting insulin prices to $35 a month but Republicans can’t have any of that. PhRMA spent pharma’s money well and bought some politicians while people who need insulin are suffering.
pharmaphorum
MAY 21, 2021
Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 10, 2021
The fundamental misconception among the public, the media and even some lawmakers is that higher drug list prices are the result of drug manufacturers being in a monopolistic position to endlessly raise prices on critical drugs like insulin and then rake in big profits. What’s Next: How Should Pharma Companies Respond?
Pharmaceutical Technology
JANUARY 31, 2023
FDA director Robert Califf gave his prognosis for the pharma industry at this year’s JP Morgan Healthcare Conference in San Francisco over January 9–12. That leaves three years for pharma companies to prepare. It’s much needed. It’s a hot area.” trillion Consolidated Appropriations Act.
pharmaphorum
JUNE 14, 2021
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.
pharmaphorum
SEPTEMBER 1, 2020
Previously a centre of the trade in textiles and dyes, Swiss manufacturers gradually began to realise their dyestuffs had antiseptic and other properties and began to market them as pharmaceuticals, in contrast to the origin in pharmacies of other enterprises. Thalidomide and the development of drug safety regulation and monitoring.
World of DTC Marketing
JUNE 16, 2021
About eight in ten across partisans say profits made by pharmaceutical companies are a “major factor” in the price of prescription drugs. The May 2021 KFF Health Tracking Poll finds about two-thirds of adults say there is “not as much regulation as there should be” when it comes to limiting the price of prescription drugs.
Expert insights. Personalized for you.
184 
Let's personalize your content